Page last updated: 2024-09-03

sulbactam and Neonatal Sepsis

sulbactam has been researched along with Neonatal Sepsis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Acman, M; Chiu, CH; Hamawandi, A; Lindsay, JA; Readman, JB; Sharland, M; Standing, JF	1

Other Studies

1 other study(ies) available for sulbactam and Neonatal Sepsis

Article	Year
Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings. The Journal of antimicrobial chemotherapy, 2023, 08-02, Volume: 78, Issue:8 Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Escherichia coli; Gentamicins; Humans; Infant, Newborn; Microbial Sensitivity Tests; Neonatal Sepsis; Prevalence; Sulbactam	2023

Article

Year

Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.

The Journal of antimicrobial chemotherapy, 2023, 08-02, Volume: 78, Issue:8

Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Escherichia coli; Gentamicins; Humans; Infant, Newborn; Microbial Sensitivity Tests; Neonatal Sepsis; Prevalence; Sulbactam

2023